Key Highlights
- Edwards Lifesciences has acquired Innovalve Bio Medical Ltd., enhancing its TMVR technologies.
- Innovalve joins the TMTT product group, led by Daveen Chopra.
- SAPIEN M3 on track to become the first approved transfemoral TMVR system in Europe by end of 2025.
- Acquisition expected to close by the end of 2024.
Source: Business Wire
Notable Quote
- “Building on our learnings of the complexity of mitral disease, we know there is a need for a differentiated range of therapies for these patients. Edwards’ SAPIEN M3 remains on track to become the first approved transfemoral TMVR system in Europe by the end of 2025. We believe the Innovalve technologies, paired with Edwards’ deep mitral expertise, will enable a TMVR platform that will expand the treatable population.” — Daveen Chopra, Corporate Vice President, TMTT Product Group at Edwards Lifesciences
SoHC's Take
The acquisition of Innovalve Bio Medical Ltd. by Edwards Lifesciences represents a significant strategic move to strengthen its portfolio in the TMVR sector. This decision is poised to not only address unmet patient needs in structural heart disease but also to potentially position Edwards as a leader in transcatheter mitral and tricuspid valve therapies. With the anticipated approval of SAPIEN M3 in Europe and the integration of Innovalve’s promising technologies, Edwards Lifesciences is well-positioned to deliver innovative and comprehensive solutions for complex mitral valve diseases, thereby driving sustainable long-term growth.
